NEOGENOMICS INC

Key metrics

Financial performance

Over the last 9 fiscal years NEOGENOMICS INC's revenue grew from $231.81M to $727.33M, a compound annual growth rate of 13.5%. Net profit margin compressed from -2.6% to -14.8% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,240 filings)

Recent press releases

• NeoGenomics Reports First Quarter 2026 Results2026-04-28

  NeoGenomics Reports First Quarter 2026 Results :: NeoGenomics, Inc. (NEO)

• NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration2026-04-23

  NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

• NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 20262026-04-07

  NeoGenomics to Present New Research at ASCO Annual Meeting 2026

• NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling2026-03-16

  NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

• NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types2026-02-25

  NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types :: NeoGenomics, Inc. (NEO)

Similar companies

The largest companies sharing NEOGENOMICS INC's SEC industry classification (services-testing laboratories).